Sensei Biotherapeutics net loss deepens to $170.2M on Faeth acquisition charges

Sensei Biotherapeutics (NASDAQ:SNSE) reported a significantly wider net loss for the first quarter of 2026, primarily driven by massive, one-time accounting charges stemming from its transformational acquisition of Faeth Therapeutics Inc. earlier in the year.

The Boston-based clinical-stage biotechnology firm posted a net loss of $170.2 million, or $131.45 per basic and diluted share, for the three months ended March 31, 2026.

This performance marks a substantial expansion against the net loss of $6.9 million, or $5.45 per share, recorded during the first quarter of 2025.

The deepening deficit was anchored by a $133 million charge for acquired in-process research and development (IPR&D), reflecting the fair value of preclinical and clinical assets obtained from Faeth that have no alternative future use.

Operating expenditures also climbed substantially during the integration period.

Research and development (R&D) expenses rose to $18 million from $3.7 million in the prior year's opening quarter, fueled by the absorption of Faeth’s active operations and immediate transaction costs, which overrode ongoing cost reductions from Sensei's legacy SNS-101 clinical trial.

Concurrently, general and administrative (G&A) overhead escalated to $19.7 million from $3.5 million a year earlier, similarly driven by one-time acquisition outlays.

Despite the heavy accounting losses, the corporate combination fundamentally reshaped the company's balance sheet.

Sensei concluded the first quarter with $202.8 million in cash, cash equivalents, and marketable securities, representing a steep increase from the $21.2 million reported at the close of fiscal year 2025.

The liquidity surge was fueled by a $200 million concurrent private placement executed alongside the Faeth transaction in February, backed by an institutional life sciences investor syndicate.

The newly reinforced capital stack is earmarked to advance Sensei's newly designated lead asset, PIKTOR, an all-oral, multi-node pathway inhibitor targeting solid tumors.